Kaletra

Selected form

Method of action: Antiretroviral Agent

Treatment option: Immunodeficiency, Infection

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kaletra

What is Kaletra? The Lopinavir/Ritonavir Combination

Property	Description
Active Ingredients	Lopinavir, Ritonavir
Form	Film-coated Tablet, Oral Solution
Pharmacological Class	Antiretroviral Agent, Protease Inhibitor (PI)
Common Use	Management of HIV-1 infection
Origin	Synthetic

The medication known by the trade name Kaletra is a fixed-dose combination product containing the two synthetic antiviral compounds, Lopinavir and Ritonavir, designed for oral administration. It is formally classified as an Antiretroviral Agent and belongs to the Protease Inhibitor (PI) pharmacological class.

Defining Lopinavir/Ritonavir: Class and Composition

Lopinavir/Ritonavir is structured so that the two active ingredients fulfill distinct yet complementary roles: Lopinavir is the primary agent responsible for the antiviral activity, while low-dose Ritonavir acts as a pharmacokinetic enhancer or booster. This combination strategy is designed to be more forgiving of non-adherence compared to earlier, un-boosted Protease Inhibitors. The Ritonavir component achieves this by inhibiting a specific liver enzyme (CYP3A4), which slows the natural breakdown of Lopinavir and ensures a consistently high and effective concentration of the primary drug in the bloodstream. This feature serves as a foundation for effective Antiretroviral Therapy (ART) regimens.

What is the General Purpose of Lopinavir/Ritonavir?

The principal purpose of Lopinavir/Ritonavir is to achieve substantial and sustained viral suppression by limiting the HIV-1 virus's capacity to reproduce and spread throughout the body. This is intended to reduce the overall viral load and help preserve the patient’s immune system function over time, thereby slowing the progression of HIV-1 infection. Lopinavir/Ritonavir is often used as a core component in combination therapy, particularly in patients who may have prior exposure to other antiretroviral medications, due to its high genetic barrier to resistance. The fixed-dose tablet formulation is further differentiated by its ability to be taken with or without food and its stability without refrigeration, offering a practical advantage for patients in diverse living situations.

What side effects are possible with Kaletra ?

Possible Side Effects and Safety Information for Kaletra

Common and Serious Adverse Reactions

The most commonly reported adverse reactions associated with Kaletra (lopinavir/ritonavir) include diarrhea, nausea, vomiting, and abdominal pain. Metabolic changes are also common, specifically elevations in total cholesterol and triglycerides (hyperlipidemia). Fat redistribution (lipodystrophy) has also been observed.

Clinically significant and serious adverse reactions reported in regulatory documents include fatalities due to pancreatitis and hepatotoxicity (liver damage). Patients with underlying hepatic disease, including Hepatitis B or C, require liver function monitoring before and during therapy. Severe hypersensitivity reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported.

Cardiovascular and Metabolic Safety

Kaletra is associated with a risk of QT and PR interval prolongation, which may lead to serious cardiac events, including second or third-degree heart block, or rare cases of Torsade de pointes. Use is typically avoided in patients with congenital long QT syndrome or hypokalemia, and caution is advised for patients with pre-existing conduction system disease or structural heart disease. Furthermore, new onset or exacerbation of diabetes mellitus/hyperglycemia has been reported, requiring blood glucose monitoring.

Restrictions and Special Populations

Kaletra is contraindicated in patients with a known hypersensitivity to its components and with numerous co-administered drugs. Co-administration is restricted with medications that are highly dependent on the CYP3A enzyme for clearance, where increased plasma levels could result in serious or life-threatening adverse reactions. The oral solution is not recommended for use in preterm neonates or in full-term neonates less than 14 days of age due to potential toxicity from the excipients (alcohol and propylene glycol).

Overdose and Emergency Response

The official regulatory documents state that immediate medical attention is required upon recognizing a suspected overdose of Lopinavir/Ritonavir. Due to the potential for severe, life-threatening outcomes, contact emergency services right away to ensure proper management.

Overdose Profile and Clinical Manifestations

No specific antidote is known for Lopinavir/Ritonavir overdose. Management consists solely of general supportive measures and continuous monitoring of the patient's condition.

Documented severe manifestations are linked to the drug's properties and, specifically, the excipients in the Oral Solution formulation. Overdose can result in severe effects on the Cardiovascular System, including Cardiac Arrhythmias, ECG changes, Complete AV Block, and potentially Cardiogenic Shock. Other documented outcomes involve the Central Nervous System (CNS Depression, Seizures) and the Metabolic/Renal System (Lactic Acidosis, Acute Renal Failure).

Population-Specific Overdose Considerations

The Oral Solution formulation carries a unique, severe overdose risk, particularly in infants and neonates, which has resulted in fatalities. This risk is attributed to the high concentrations of the excipients alcohol and propylene glycol. Regulatory guidance mandates Continuous ECG Monitoring and close observation of vital signs in overdose situations. Gastric lavage may be considered if ingestion is recent, but hemodialysis is unlikely to remove the drug effectively.

Therapeutic Uses of Kaletra

What Kaletra treats: main uses and benefits

The fixed-dose combination of Lopinavir/Ritonavir is generally used for the treatment and long-term management of Human Immunodeficiency Virus type 1 (HIV-1) infection. This therapeutic option is applied in patients across multiple age groups, including adults, adolescents, and pediatric patients. It is also utilized during pregnancy, as part of a combination regimen, where it contributes to the overall support needed for managing the risk of transmission to the child.

A primary goal of the therapy is to support the management of viral suppression. By managing the amount of detectable virus (viral load), the medication supports the patient's immune system, which in turn may assist with managing the disease progression and assists with managing the overall symptom load associated with immunosuppression. This makes it a component for treatment-naïve patients and those with previous treatment challenges (treatment-experienced patients or virological failure).

“This medication may assist with stabilizing the patient’s general well-being by supporting immune system function over time.”

Quick Fact: Supports Management of Immunological Decline

The treatment supports functional stability and general well-being by helping to preserve immune cell counts, which helps manage symptoms related to immunological decline.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Kaletra (lopinavir/ritonavir) is officially approved for use in adults, adolescents, and pediatric patients aged 14 days and older. Regulatory documents explicitly define who must not use the medicine and which groups require conditional use.

Eligibility Status	Official Regulatory Classification
Allowed Populations	Adults, adolescents, and children 14 days of age and older.
Contraindicated	Patients with severe hepatic insufficiency or known hypersensitivity to any of the ingredients.
Not Recommended	Individuals who are breastfeeding due to the risk of HIV transmission to the infant.

Age and Condition-Based Restrictions

The oral solution is contraindicated in preterm neonates and must not be administered to any neonate before a postnatal age of 14 days is reached. Use is generally advised with caution in patients with mild to moderate hepatic impairment and in older adults, who may have reduced liver, kidney, or heart function. The label also advises avoiding use in patients with conditions that prolong the QT interval, such as congenital long QT syndrome.

What should I know about interactions with other medicines?

Kaletra (lopinavir/ritonavir) has an extensive drug-drug interaction profile that requires careful consideration of all co-administered products. This is primarily because its component, ritonavir, is used to boost the levels of lopinavir by acting as a potent inhibitor of the major metabolic enzyme CYP3A4.

Contraindicated Combinations

Due to this strong enzyme inhibition, Kaletra is contraindicated (must not be used) with medicines that are highly dependent on CYP3A for clearance, as increased blood levels could lead to serious or life-threatening reactions. This includes: the anti-anginal ranolazine; the antiarrhythmic dronedarone; the anti-psychotics pimozide and quetiapine; the GI motility agent cisapride; certain HMG-CoA reductase inhibitors (statins) like lovastatin and simvastatin; and ergot derivatives such as ergotamine.

Kaletra is also contraindicated with potent CYP3A inducers—such as rifampin, St. John's wort, carbamazepine, phenobarbital, and phenytoin—because they can significantly lower lopinavir concentrations, potentially leading to loss of virologic response and drug resistance.

Dose Adjustments

When co-administered with other antiretrovirals like efavirenz, nevirapine, or nelfinavir, a dose increase of Kaletra is mandated to compensate for their effects on lopinavir clearance. The once-daily Kaletra dosing regimen is not recommended with these specific antiretrovirals or the aforementioned potent CYP3A inducers.

Mechanism of Action

How Kaletra Works: The Dual-Action Mechanism

Molecular Interruption of Viral Maturation

This domain describes the primary antiviral activity where Lopinavir acts as a peptidomimetic inhibitor that directly targets the HIV-1 Protease enzyme. By binding tightly to the enzyme's active site, Lopinavir physically stops the necessary cleavage of the viral polyprotein precursors. This molecular blockade arrests the viral maturation cycle, leading to the formation of immature, non-infectious viral particles. This mechanism initiates the cascade that results in the reduction of the systemic viral load.

Enzyme-Mediated Metabolism Inhibition

This domain covers the synergistic role of Ritonavir, which acts as a metabolism inhibitor rather than a primary antiviral agent. Ritonavir is an inhibitor of the host metabolic enzyme Cytochrome P450 3A4 (CYP3A4), the primary enzyme for Lopinavir's metabolism and clearance. This inhibition modulates the drug's elimination pathway, ensuring Lopinavir's concentration in the bloodstream remains consistently high and stable. This leads to continuous saturation of the HIV-1 Protease target, supporting the continuous nature of the viral maturation blockade.

Dosage and Administration Information

General Administration Guidelines for Kaletra

The administration of the combination medicine Kaletra (lopinavir/ritonavir) is determined by the dosage form, patient population, and concurrent medications.

Administration Scope	Standard Instruction
Route of Administration	Oral
Standard Adult Dose	400 mg Lopinavir / 100 mg Ritonavir twice daily OR 800 mg Lopinavir / 200 mg Ritonavir once daily (if specific virological conditions are met).
Timing in Relation to Meals	Film-coated tablets may be taken with or without food; the oral solution is taken with food.
Tablet Preparation	Tablets are swallowed whole and are not to be chewed, broken, or crushed.
Missed Dose Protocol	If a dose is missed, it is typically taken as soon as remembered. If it is almost time for the next dose, the missed dose is skipped, and the regular schedule resumed. The dose is not doubled.

Population-Specific Use

Twice-daily dosing is the regimen utilized for pediatric patients and pregnant patients. Pediatric dosage is calculated based on body weight (kg) or body surface area (m^2). The once-daily regimen is not recommended for patients with certain drug-resistance associated substitutions or when taken with medications like efavirenz or nevirapine.

Recent Clinical Evidence

Research evidence / Overview of studies for Kaletra

This section provides a summary of the types of research and clinical trials that have been conducted to evaluate the combination medicine Lopinavir/Ritonavir (Kaletra), focusing only on what has been observed and what remains uncertain according to official sources. The findings reflect group patterns and not personal outcomes.

Evidence for Initial Treatment of HIV-1 Infection

For individuals who are starting antiretroviral therapy for the first time, researchers conducted multiple Randomized Controlled Trials (RCTs). These studies were used to compare the Lopinavir/Ritonavir combination against other standard anti-HIV treatment regimens. The main focus of these trials was to measure the proportion of patients who achieved viral load suppression, where the studied outcome is defined by achieving a specified low threshold of measurable HIV-1 virus in the blood. Studies also monitored the patient's CD4+ T-cell count, a measure used in research as an immune system biomarker.

Research describes patterns observed related to the measurable presence of the HIV-1 virus during the study period. Studies also monitored the measured changes in CD4+ cell counts during the course of the trials. Some long-term follow-up studies described the sustained maintenance of measured outcomes over periods extending past three years. What remains uncertain for this population involves long-term outcomes, particularly the sustained maintenance of the effect after many years (beyond four years).

Evidence for Use in Treatment-Experienced HIV-1 Infection

Research examined the use of this medicine in patients who had previously taken other antiretroviral drugs and experienced virological failure. Studies utilized Randomized Controlled Trials (RCTs) to compare the combination drug against other protease inhibitors in patients with various levels of existing drug resistance. The study outcomes examined included achieving or re-establishing viral load suppression. Findings describe patterns observed in studies of patients who were investigated following prior virological failure. The complexity of resistance profiles in this population means that the relationship between existing mutations and long-term sustained viral suppression is still subject to ongoing study.

Evidence in Pediatric Patients

Research has also explored the use of the medicine in specific groups, including infants (starting from 14 days of age), children, and adolescents. These studies included dedicated pharmacokinetic (PK) trials which focused on how the medicine is absorbed and processed in the body. Reports described that achieving appropriate drug exposure in infants aged less than 12 months was associated with lower levels than those found in adults. Research regarding the appropriate dose for infants younger than 14 days of age is limited.

Frequently Asked Questions (FAQ)

Common questions about Kaletra (FAQ)

Q: What is Kaletra used for?

A: Kaletra (lopinavir/ritonavir) is an antiretroviral medication. It is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and in pediatric patients 14 days of age and older.

Q: Does Kaletra reduce the viral load in the body?

A: Clinical studies indicate that Kaletra, when used in combination with other antiretroviral medicines, is associated with a reduction in the amount of HIV-1 virus in the blood (viral load) to very low levels. This observed reduction may help to slow the progression of HIV-related disease.

Q: What benefits were observed in clinical trials for Kaletra?

A: In clinical trials involving adults who had not previously received HIV treatment, a high percentage of patients taking Kaletra achieved very low viral load levels after 24 weeks. Similarly, studies involving patients previously treated with a protease inhibitor also showed that a majority of those taking Kaletra attained very low viral load levels after 16 weeks. Studies in children have shown similar observations regarding viral load levels after 48 weeks of treatment.

Q: How does Kaletra relate to the immune system?

A: By helping to reduce the amount of HIV-1 virus in the blood, Kaletra, when used as part of a combination regimen, is associated with an increase in CD4+ cell counts. The increase in CD4+ cells, which are important for immune function, is observed to support the overall immune system and may reduce the development of infections related to a weakened immune system.

Q: Is Kaletra a cure for HIV or AIDS?

A: No, Kaletra is not a cure for HIV-1 infection or AIDS. The medication is used as part of a comprehensive treatment plan to manage the infection.

Q: What are the active ingredients in Kaletra?

A: Kaletra is a fixed-dose combination medication containing two active substances: lopinavir and ritonavir. Lopinavir is an HIV protease inhibitor, and ritonavir acts as a pharmacokinetic booster to slow the breakdown of lopinavir.

Q: Are there common side effects associated with Kaletra?

A: The most frequently reported side effects in clinical trials include diarrhea, nausea, and vomiting. Other common side effects may include upper respiratory tract infection and abdominal pain. Patients are encouraged to discuss potential side effects with a healthcare provider.

Q: Can Kaletra be taken during pregnancy?

A: The use of Kaletra during pregnancy requires specific dosing considerations. The oral solution formulation contains alcohol and propylene glycol and should be avoided during pregnancy due to the risk associated with alcohol exposure. Pregnant patients should consult their healthcare provider for appropriate dosing and formulation guidance.

How should Kaletra be stored and disposed of?

How to Store and Dispose of Kaletra

Formulation	Required Storage Condition	Stability/Time Limit
Film-Coated Tablets	Room Temperature (20 C to 25 C). Keep in original container, tightly closed, away from moisture.	Do not keep out of the container for more than two weeks.
Oral Solution	Refrigerated (2 C to 8 C). Do not freeze.	May be used until the expiration date if refrigerated. If stored at room temperature (less than 25 C), use within two months.

All forms of Kaletra must be stored out of the sight and reach of children for safety. Unused or expired medicine must be thrown away. Disposal should follow established guidelines from health authorities to avoid flushing or placing medication in household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.